ATHAAthira Pharma, Inc.

ATHA Stock Price, Valuation & Chart | Athira Pharma, Inc.

Compare

$6.750-0.44 (-6.12%)

At close · 09 Jan 2026, 09:00 pm

Sector: Healthcare Industry: Biotechnology ATHA intrinsic value ATHA calculated fair value vs price

Overview Financials Dividends Ratios

ATHA Historical price chart

ATHA Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization26.62M

PE Ratio-0.7

EPS-9.67

Trading Volume70.31K

Today's High/Low7.35/6.61

Dividend Yield0.00

52 Week High/Low8.36/2.2

Shares Outstanding3.94M

ATHA Financial Statement

ATHA Analyst ratings

ATHA Analysis & performance metrics

ATHA Company profile

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The…

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's…

ATHA Management team

Name

Position

Javier San Martin M.D.

Chief Medical Officer

Mark F. Worthington J.D.

General Counsel, Chief Compliance Officer & Corporate Secretary

Julie Rathbun

Head of Investor Relations

Kevin Church Ph.D.

Chief Scientific Officer

Robert Renninger

Senior Vice President of Finance & Accounting, Principal Financial Officer and Principal Accounting Officer

Mark J. Litton M.B.A., Ph.D.CEO

President, Chief Executive Officer & Director

Name

Position

Javier San Martin M.D.

Chief Medical Officer

Mark F. Worthington J.D.

General Counsel, Chief Compliance Officer & Corporate Secretary

Julie Rathbun

Head of Investor Relations

Kevin Church Ph.D.

Chief Scientific Officer

Robert Renninger

Senior Vice President of Finance & Accounting, Principal Financial Officer and Principal Accounting Officer

Mark J. Litton M.B.A., Ph.D.CEO

President, Chief Executive Officer & Director

Management Team

Javier San Martin M.D.

Chief Medical Officer

Mark F. Worthington J.D.

General Counsel, Chief Compliance Officer & Corporate Secretary

Julie Rathbun

Head of Investor Relations

Kevin Church Ph.D.

Chief Scientific Officer

Robert Renninger

Senior Vice President of Finance & Accounting, Principal Financial Officer and Principal Accounting Officer

Mark J. Litton M.B.A., Ph.D.CEO

President, Chief Executive Officer & Director

Management

Javier San Martin M.D.

Chief Medical Officer

Mark F. Worthington J.D.

General Counsel, Chief Compliance Officer & Corporate Secretary

Julie Rathbun

Head of Investor Relations

Kevin Church Ph.D.

Chief Scientific Officer

Robert Renninger

Senior Vice President of Finance & Accounting, Principal Financial Officer and Principal Accounting Officer

Mark J. Litton M.B.A., Ph.D.CEO

President, Chief Executive Officer & Director

Total 6 executives

ATHA Frequently asked questions

What is Athira Pharma, Inc. (ATHA) Stock Price?

Current stock price of Athira Pharma, Inc. (ATHA) stock is $6.750. The stock price is -6.12% lower in the session. The intraday range can be seen from this page. Volume of Athira Pharma, Inc. (ATHA) stock is 70.31K.

Last updated at 09 Jan 2026, 09:00 pm.

Why is the Athira Pharma, Inc. (ATHA) stock price going up or down today?

The stock price of Athira Pharma, Inc. (ATHA) can change with earnings, company news, and overall market sentiment. Athira Pharma, Inc. operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Athira Pharma, Inc. stock expensive at its current price?

Whether Athira Pharma, Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for ATHA on this page is -0.70. EPS on this page is -9.67. Compare those figures with peers and growth expectations before deciding if the current Athira Pharma, Inc. price is justified.

How has the stock price of Athira Pharma, Inc. (ATHA) performed historically?

Historical performance for Athira Pharma, Inc. (ATHA) is shown on the price chart on this page. Review multi-period moves alongside volume to see how ATHA reacted to past earnings and market events.

Should I buy Athira Pharma, Inc. (ATHA) stock, at this price?

Buying Athira Pharma, Inc. (ATHA) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.